Pathstone Family Office’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $900 | Hold |
10,043
| – | – | ﹤0.01% | 1655 |
|
|
2023
Q2 | $924 | Hold |
10,043
| – | – | ﹤0.01% | 1235 |
|
|
2023
Q1 | $2.61K | Sell |
10,043
-10,043
| -50% | -$2.61K | ﹤0.01% | 1184 |
|
|
2022
Q4 | $70.6K | Sell |
20,086
-14
| -0.1% | -$49 | ﹤0.01% | 1451 |
|
|
2022
Q3 | $5.54K | Buy |
20,100
+10,050
| +100% | +$2.77K | ﹤0.01% | 1448 |
|
|
2022
Q2 | $7.24K | Hold |
10,050
| – | – | ﹤0.01% | 1035 |
|
|
2022
Q1 | $8K | Hold |
10,050
| – | – | ﹤0.01% | 947 |
|
|
2021
Q4 | $10K | Hold |
10,050
| – | – | ﹤0.01% | 883 |
|
|
2021
Q3 | $17K | Hold |
10,050
| – | – | ﹤0.01% | 850 |
|
|
2021
Q2 | $18K | Hold |
10,050
| – | – | ﹤0.01% | 804 |
|
|
2021
Q1 | $20K | Hold |
10,050
| – | – | ﹤0.01% | 636 |
|
|
2020
Q4 | $22K | Hold |
10,050
| – | – | ﹤0.01% | 672 |
|
|
2020
Q3 | $28K | Hold |
10,050
| – | – | ﹤0.01% | 438 |
|
|
2020
Q2 | $39K | Hold |
10,050
| – | – | ﹤0.01% | 345 |
|
|
2020
Q1 | $8K | Hold |
10,050
| – | – | ﹤0.01% | 576 |
|
|
2019
Q4 | $127K | Buy |
10,050
+2,525
| +34% | +$31.9K | ﹤0.01% | 414 |
|
|
2019
Q3 | $5K | Hold |
7,525
| – | – | ﹤0.01% | 538 |
|
|
2019
Q2 | $5K | Hold |
7,525
| – | – | ﹤0.01% | 564 |
|
|
2019
Q1 | $21K | Buy |
+7,525
| New | +$21K | ﹤0.01% | 429 |
|